Why this pharma is sitting pretty

Posted 9 February 2024 AM

Winning earlier-than-expected blockbuster status for one of its products in 2023 seems to have set GSK on a roll.

The company's RSV vaccine, Arexvy, launched last year in the US with expectations of high sales, but not so soon. In its third quarter earnings release, GSK predicted sales of Arexvy would be between $1.7 billion and $1.9 billion for the full year. In fact, the vaccine roared to blockbuster status by pulling in $2.4 billion for 2023.

To see the whole article, please login